Clinical Trials for Sulindac

1 Open Trial

Trial TypeProtocol No. &
Open Date
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.